North Chicago:AbbViehas announced that it has completed itsacquisitionof Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD). This next-generation 5-HT2A receptor agonist is designed to help address current development challenges observed with classic psychedelic compounds. "Recent clinical results have demonstrated the potential of bretisilocin to treat patients living with MDD," said Daniel Mikol, M.D., Ph.D., vice president, neuroscience development, AbbVie. "With the acquisition now complete, we look forward to accelerating the development of this next-generation compound, reinforcing AbbVie's commitment to delivering innovative, science-driven treatment options for people living with serious mental health conditions." Read also:Abbvie gets USFDA approval for updated indication statement for Rinvoq for Inflammatory Bowel Disease
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!